We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global POC Diagnostics Devices and Equipment Market to Surpass USD 50 Billion in 2026

By LabMedica International staff writers
Posted on 08 Jun 2022

Point-of-care (POC) diagnostics devices and equipment are designed to aid physicians in performing medical diagnostic testing at or near the point of care, for immediate knowledge on diseases or conditions. More...

An increase in the incidence of target diseases is driving the POC devices and equipment market globally. The rising incidence of chronic diseases, like diabetes, rheumatism, or cancer is increasing steadily worldwide due to poor lifestyle choices and increasing obesity, thus driving the growth of the POC devices and equipment market. The global POC diagnostics devices and equipment market is expected to grow at a CAGR of 17.6% from USD 24.44 billion in 2021 to USD 28.74 billion in 2022 and is projected to grow further at a CAGR of 15.8% to reach USD 51.73 billion in 2026.

These are the latest findings of Research and Markets (Dublin, Ireland), the world’s largest market research store.

POC diagnostic devices and equipment comprise mainly infectious disease testing kits, cardiometabolic monitoring kits, cholesterol testing kits, pregnancy and fertility tests kits, tumor/cancer markers, urinalysis testing kits, hematology testing kits, drugs of abuse testing kits, fecal occult testing kits, and others. Pregnancy and fertility tests kits in POC diagnostic devices are used to test for pregnancy and fertility in advance before going to the doctor.

POC diagnostic devices and equipment includes prescription-based and over-the-counter (OTC) testing devices which have a large base of end-users such as professional diagnostic centers, hospitals/critical care centers, outpatient healthcare settings, ambulatory care settings, research laboratories, and homes. OTC testing is being seen as a key growth driver of the POC diagnostics market as it improve access to testing and enables early detection of diseases. The US FDA has approved OTC test kits for cholesterol, fecal occult blood, pregnancy, and HIV/HCV. These testing kits are likely to generate more revenue than prescription tests over the forecast period due to ease of using the kits, increased home care and self-testing, and a rise in their availability and adoption rate. In 2021, North America was the largest POC diagnostic devices and equipment market followed by the Asia Pacific region.

Related Links:
Research and Markets 


New
Gold Member
Hybrid Pipette
SWITCH
Portable Electronic Pipette
Mini 96
ESR Analyzer
TEST1 2.0
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.